TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8503670

Group type: EXPERIMENTAL
Intervention: Autohaler inhalation device
Number of subjects: 51

Group type: COMPARATOR
Intervention: Rotahaler
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Both inhalers
Number of subjects: 51
Study: 3729353

Group type: EXPERIMENTAL
Intervention: Azlocillin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Piperacillin
Number of subjects: 0
Study: 29642628

Group type: EXPERIMENTAL
Intervention: Social network-based intervention (SNI) promoting water consumption among children
Number of subjects: 377

Group type: COMPARATOR
Intervention: Control group (CG) with no intervention
Number of subjects: 377
Study: 27030142

Group type: EXPERIMENTAL
Intervention: GNbAC1 (6, 18, and 36 mg/kg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 25573021

Group type: EXPERIMENTAL
Intervention: APC combined with SB
Number of subjects: 90

Group type: COMPARATOR
Intervention: APC alone
Number of subjects: 90

Group type: COMPARATOR
Intervention: SB alone
Number of subjects: 90
Study: 22562730

Group type: EXPERIMENTAL
Intervention: Concurrent strength and continuous running training (SCR)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Concurrent strength and interval running training (SIR)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Concurrent strength and continuous cycle ergometer training (SCE)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Strength training only (STO)
Number of subjects: 44
Study: 19709658

Group type: EXPERIMENTAL
Intervention: Non-specific immunomodulation therapy (IMT), autologous blood exposed to oxygen/ozone gas mixture by intragluteal injection, administered on day 1, 2, 7, and once a week thereafter for at least 22 weeks.
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo, administered to control group (n=74).
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Non-specific immunomodulation therapy (IMT).
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo.
Number of subjects: 151
Study: 18489229

Group type: EXPERIMENTAL
Intervention: Progressive training in auditory identification tasks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Extensive training with highly similar sounds
Number of subjects: 0
Study: 11395345

Group type: EXPERIMENTAL
Intervention: Nurse-led multidimensional preventive programme (n = 250)
Number of subjects: 503

Group type: COMPARATOR
Intervention: Control group (n = 249)
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Nurse-led multidimensional preventive programme
Number of subjects: 503
Study: 9513325

Group type: EXPERIMENTAL
Intervention: Low dose midazolam (MZ) administered i.v. at doses of 0, 0.03, 0.06 mg.kg‐1
Number of subjects: 70

Group type: COMPARATOR
Intervention: No premedication (group N)
Number of subjects: 70
Study: 8151609

Group type: EXPERIMENTAL
Intervention: Amlodipine (5‐10 mg once daily)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Nifedipine retard (20‐40 mg twice daily)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 111

Group type: COMPARATOR
Intervention: Nifedipine retard
Number of subjects: 111
Study: 2855391

Group type: EXPERIMENTAL
Intervention: Gastrocote (alginic acid, aluminium hydroxide gel, magnesium trisilicate, sodium bicarbonate) 2 tablets q.d.s.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg q.d.s.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined therapy (Cimetidine and Gastrocote)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gastrocote
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined therapy
Number of subjects: 0
Study: 31179505

Group type: EXPERIMENTAL
Intervention: Cervical headgear with light force (300 g)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cervical headgear with heavy force (500 g)
Number of subjects: 40
Study: 28109570

Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment (OMT)
Number of subjects: 80
Study: 25627646

Group type: EXPERIMENTAL
Intervention: Specific resistance training program (throwing movement with a medicine ball)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Regular throwing training (throwing with regular balls)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study: 22895636

Group type: EXPERIMENTAL
Intervention: Game-based pedagogy for sustainability ethics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional professional ethics education
Number of subjects: 0
Study: 21871056

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 76

Group type: COMPARATOR
Intervention: Conventional insulin therapy
Number of subjects: 76
Study: 17562336

Group type: EXPERIMENTAL
Intervention: GnRH agonist, low‐dose GnRH antagonist, and estradiol valerate followed by recombinant FSH, 600 IU/day (n = 72)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: GnRH agonist, low‐dose GnRH antagonist, and estradiol valerate followed by recombinant FSH, 750 IU/day (n = 65)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: GnRH agonist, low‐dose GnRH antagonist, and estradiol valerate followed by recombinant FSH, 600 IU/day
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: GnRH agonist, low‐dose GnRH antagonist, and estradiol valerate followed by recombinant FSH, 750 IU/day
Number of subjects: 137
Study: 16844889

Group type: EXPERIMENTAL
Intervention: Clinical depression (Beck Depression Inventory)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Clinical anxiety (Beck Anxiety Inventory)
Number of subjects: 179
Study: 12404072

Group type: EXPERIMENTAL
Intervention: 5 mg hydrocodone/1.5 mg homatropine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 10 mg hydrocodone/3 mg homatropine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 20 mg hydrocodone/6 mg homatropine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 40 mg morphine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 2 mg lorazepam
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 10705173

Group type: EXPERIMENTAL
Intervention: Teprenone 1.5 g/day for 8 weeks (PHG(+)‐t)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Teprenone 1.5 g/day for 8 weeks (PHG(‐)‐t)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No treatment (PHG(+)‐n)
Number of subjects: 45
Study: 9552427

Group type: EXPERIMENTAL
Intervention: Lopressor (metoprolol tartrate)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Slow-dissolving formulation
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Medium-dissolving formulation
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Fast-dissolving formulation
Number of subjects: 4
Study: 8400793

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH)
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 31531949

Group type: EXPERIMENTAL
Intervention: Anti-TB medications
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (TB patients without gout attacks)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Higher BMI, CKD, and pre-treatment hyperuricemia (SUA ≥ 6.8 mg/dL)
Number of subjects: 49
Study: 30541250

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 84

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 84
Study: 27827331

Group type: EXPERIMENTAL
Intervention: Physician-led video
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Subject-generated community video
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Both physician-led and subject-generated videos
Number of subjects: 87

Group type: COMPARATOR
Intervention: Educational pamphlet (control group)
Number of subjects: 87
Study: 25200587

Group type: EXPERIMENTAL
Intervention: EAT thickness measured via echocardiography in patients with CAD
Number of subjects: 153

Group type: COMPARATOR
Intervention: EAT thickness measured via echocardiography in patients without CAD
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: EAT thickness from parasternal short-axis view in patients with CAD
Number of subjects: 153

Group type: COMPARATOR
Intervention: EAT thickness from parasternal short-axis view in patients without CAD
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Correlation of EAT thickness with age
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Correlation of EAT thickness with waist circumference
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Correlation of EAT thickness with cholesterol-HDL
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Correlation of EAT thickness with serum adiponectin
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Correlation of EAT thickness with severity of CAD
Number of subjects: 153
Study: 22704944

Group type: EXPERIMENTAL
Intervention: Oxybuprocaine hydrochloride 0.4%
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 30
Study: 20649056

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 400 mg intravenously every 8 h
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ciprofloxacin 400 mg intravenously every 12 h
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 10
Study: 19146604

Group type: EXPERIMENTAL
Intervention: Hydradermabrasion with polyphenolic antioxidant serum (Group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Manual application of polyphenolic antioxidant serum (Group B)
Number of subjects: 20
Study: 16934148

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics via the respiratory tract (gentamicin, polymyxins, tobramycin, ceftazidime)
Number of subjects: 1877

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 1877

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics via the respiratory tract
Number of subjects: 1877
Study: 12564612

Group type: EXPERIMENTAL
Intervention: Breathlessness, Cough and Sputum Scale (BCSS)
Number of subjects: 629
Study: 10970930

Group type: EXPERIMENTAL
Intervention: Home program of rehabilitation including guidance on home activities and weekly telephone calls from a psychiatric nurse.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inpatient cognitive rehabilitation (control group).
Number of subjects: 0
Study: 8970416

Group type: EXPERIMENTAL
Intervention: d-sotalol (1.5 mg/kg, intravenous)
Number of subjects: 28

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 28
Study: 1597846

Group type: EXPERIMENTAL
Intervention: DTZ SR/HCTZ (120/12.5 mg)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: DTZ SR/HCTZ (60/6.25 mg)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: DTZ SR/HCTZ (90/6.25 mg)
Number of subjects: 298

Group type: COMPARATOR
Intervention: HCTZ (6.25, 6.25, 12.5 mg twice daily)
Number of subjects: 298

Group type: COMPARATOR
Intervention: DTZ SR (60, 90, 120 mg twice daily)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study: 4093916

Group type: EXPERIMENTAL
Intervention: 14 valent pneumococcal vaccine
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 31210018

Group type: EXPERIMENTAL
Intervention: Video consultations
Number of subjects: 102

Group type: COMPARATOR
Intervention: Traditional consultations
Number of subjects: 102
Study: 29153273

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (8 sessions)
Number of subjects: 8
Study: 26869076

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Suicide Prevention (CBSP) therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 60
Study: 25257667

Group type: EXPERIMENTAL
Intervention: Ultrasonography screening for breast cancer
Number of subjects: 376
Study: 22699129

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine 1.5 mg/kg bolus followed by continuous infusion of 1.5 mg/kg/h, stopped 1 hour after skin closure
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 36
Study: 20585115

Group type: EXPERIMENTAL
Intervention: SM-RIF for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: SM-RIF for 4 weeks followed by RIF-CLA for 4 weeks
Number of subjects: 0
Study: 17909305

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy for 12 weeks followed by medroxyprogesterone acetate for 2 weeks
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 15516532

Group type: EXPERIMENTAL
Intervention: Sildenafil (3 x 40 mg/day for 6 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 11801428

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial electrical stimulation with a train of 5 stimuli of 50 micros duration, interstimulus interval of 5 ms, and intensity of 500 V
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Epidural recordings of corticospinal volleys
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Interstimulus interval of 5 ms
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Corticospinal volleys
Number of subjects: 100
Study: 9459371

Group type: EXPERIMENTAL
Intervention: 500 mg ascorbic acid/d (high-C diet)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Low-C diet (50 mg ascorbic acid/d)
Number of subjects: 36
Study: 7629982

Group type: EXPERIMENTAL
Intervention: Azithromycin (1.0 g as a single oral dose)
Number of subjects: 452

Group type: COMPARATOR
Intervention: Doxycycline (100 mg taken orally twice daily for 7 days)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Azithromycin (for those infected with C trachomatis)
Number of subjects: 452

Group type: COMPARATOR
Intervention: Doxycycline (for those infected with C trachomatis)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Azithromycin (for those infected with U urealyticum)
Number of subjects: 452

Group type: COMPARATOR
Intervention: Doxycycline (for those infected with U urealyticum)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 452

Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 452
Study: 2775615

Group type: EXPERIMENTAL
Intervention: Levodopa (50 mg) administered intravenously
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levodopa (250 mg) administered orally
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levodopa (50 mg) administered intravenously in the presence of carbidopa
Number of subjects: 0
Study: 408312

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Number of subjects: 51

Group type: COMPARATOR
Intervention: Air (Control)
Number of subjects: 51
Study: 30066465

Group type: EXPERIMENTAL
Intervention: Dexamethasone group (20 mL bupivacaine 0.5% + 2 mL dexamethasone 8 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (20 mL bupivacaine 0.5% + 2 mL normal saline)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dexamethasone group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 29157469

Group type: EXPERIMENTAL
Intervention: Non-individualised homeopathy
Number of subjects: 26
Study: 24715230

Group type: EXPERIMENTAL
Intervention: Subconjunctival and/or intrastromal injections of 5 mg/0.2 ml Bevacizumab (3 injections)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no Bevacizumab injections)
Number of subjects: 27
Study: 23157561

Group type: EXPERIMENTAL
Intervention: High-Intervention (HI) group adopting Mediterranean diet
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Low-Intervention (LI) group adopting Mediterranean diet
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study: 21777886

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stents with prolonged drug release (ZES-SR)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Zotarolimus-eluting stents with faster kinetics (ZES-FR)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: ZES-SR
Number of subjects: 43

Group type: COMPARATOR
Intervention: ZES-FR
Number of subjects: 43
Study: 19716142

Group type: EXPERIMENTAL
Intervention: Plasma adiponectin
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Plasma leptin
Number of subjects: 256
Study: 16454147

Group type: EXPERIMENTAL
Intervention: Magnolia officinalis and Phellodendron amurense extracts (250 mg capsules, 3 times a day for 6 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo capsules (identical to treatment)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Magnolia officinalis and Phellodendron amurense extracts
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both treatment and placebo groups
Number of subjects: 28
Study: 12826696

Group type: EXPERIMENTAL
Intervention: Testosterone (T) gel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dihydrotestosterone (DHT) gel
Number of subjects: 0
Study: 10808696

Group type: EXPERIMENTAL
Intervention: Continuous hormonal replacement therapy (HRT) with conjugated equine estrogen 0.625 mg/day and medroxyprogesterone acetate 2.5 mg/day for 21.3 +/- 9.5 months.
Number of subjects: 38

Group type: COMPARATOR
Intervention: No hormonal replacement therapy (Control group).
Number of subjects: 38
Study: 8625757

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1599726

Group type: EXPERIMENTAL
Intervention: Two-visit intervention group (risk assessment, support, cessation date setting, self-help literature, nicotine gum prescription)
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Two-visit intervention group with additional four supportive follow-up visits
Number of subjects: 647

Group type: COMPARATOR
Intervention: Two-visit intervention group (brief intervention)
Number of subjects: 647

Group type: COMPARATOR
Intervention: Two-visit intervention group with follow-up visits
Number of subjects: 647
Study: 4060998

Group type: EXPERIMENTAL
Intervention: Epidural nicomorphine post-operatively
Number of subjects: 163

Group type: COMPARATOR
Intervention: Intramuscular opiates post-operatively
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Epidural group
Number of subjects: 163

Group type: COMPARATOR
Intervention: Intramuscular group
Number of subjects: 163
Study: 27881624

Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy self-help intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30579505

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 16800

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 16800

Group type: EXPERIMENTAL
Intervention: Moderate multi-morbidity
Number of subjects: 16800

Group type: EXPERIMENTAL
Intervention: High multi-morbidity
Number of subjects: 16800

Group type: COMPARATOR
Intervention: No multi-morbidity
Number of subjects: 16800
Study: 28545041

Group type: EXPERIMENTAL
Intervention: Early measles vaccine (MV) at 18 weeks of age
Number of subjects: 512

Group type: COMPARATOR
Intervention: Control group (no early MV)
Number of subjects: 512
Study: 25457820

Group type: EXPERIMENTAL
Intervention: Distraction Osteogenesis (DO)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Bilateral Sagittal Split Osteotomy (BSSO)
Number of subjects: 66
Study: 23819119

Group type: EXPERIMENTAL
Intervention: M group with reflective markers
Number of subjects: 50

Group type: COMPARATOR
Intervention: NM group without reflective markers
Number of subjects: 50
Study: 22308653

Group type: EXPERIMENTAL
Intervention: Herbal ointment containing cinnamon, ginger, mastic (Saghez) and sesame oil applied twice a day for six weeks
Number of subjects: 92

Group type: COMPARATOR
Intervention: Salicylate ointment applied twice a day for six weeks
Number of subjects: 92
Study: 20011859

Group type: EXPERIMENTAL
Intervention: Clonidine 100 microg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clonidine 200 microg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 16495243

Group type: EXPERIMENTAL
Intervention: Telavancin at 10 mg/kg intravenously every 24 h
Number of subjects: 195

Group type: COMPARATOR
Intervention: Standard therapy (antistaphylococcal penicillin at 2 g q6h or vancomycin at 1 g q12h)
Number of subjects: 195
Study: 15535882

Group type: EXPERIMENTAL
Intervention: Physical therapy (patient education and exercise therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: General practitioners management only (control)
Number of subjects: 0
Study: 11288212

Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy
Number of subjects: 40
Study: 9209606

Group type: EXPERIMENTAL
Intervention: Ketamine (2.5 +/- 0.9 mg.kg-1.h-1) and midazolam (0.15 +/- 0.07 mg.kg-1.h-1)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sufentanil/midazolam
Number of subjects: 25
Study: 7965152

Group type: EXPERIMENTAL
Intervention: BMIPP uptake
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: BMIPP and MIBI uptake
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Matched defects
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Mismatching
Number of subjects: 22
Study: 3331041

Group type: EXPERIMENTAL
Intervention: 500 mg b.i.d. (suspended in saline)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: 500 mg t.i.d. (suspended in saline)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: 750 mg b.i.d. (suspended in 1% lidocaine)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Combination of two regimens
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: All doses
Number of subjects: 346
Study: 28639086

Group type: EXPERIMENTAL
Intervention: LCD1
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: LCD2
Number of subjects: 32

Group type: COMPARATOR
Intervention: Pelli‐Robson (printed version)
Number of subjects: 32
Study: 27287751

Group type: EXPERIMENTAL
Intervention: Rethink your Smoking program (RSP)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Minimal Intervention (MI) program
Number of subjects: 199

Group type: COMPARATOR
Intervention: No intervention (Control group)
Number of subjects: 199
Study: 24944058

Group type: EXPERIMENTAL
Intervention: MSG/IMP+ (monosodium glutamate and inosine 5'-monophosphate added to soup)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: High-carbohydrate and -protein soup
Number of subjects: 26

Group type: COMPARATOR
Intervention: MSG/IMP- (soup without added monosodium glutamate and inosine 5'-monophosphate)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: MSG/IMP+
Number of subjects: 26
Study: 23093347

Group type: EXPERIMENTAL
Intervention: Teriparatide (28.2 or 56.5 μg injection)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30